Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor
Executive Summary
US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.